Benefits
Reduced hot flashes and night sweats
Gudise 2024 (multicenter RCT, peri/postmenopausal women) showed Aspurūs™ produced positive and significant reduction in hot flashes and night sweats vs placebo. Manufacturer reports support 85% reduction in hot flashes within 4 weeks and 90% reduction in night sweats within 8 weeks in their internal trial data.
Improved sleep and reduced insomnia
Gudise 2024 found significant improvement in Regensburg Insomnia Scale scores in the Shatavari group. Manufacturer data references 60% reduction in sleeplessness vs placebo. Sleep quality is one of the most disruptive menopausal symptoms — addressing it has meaningful quality-of-life impact.
Anxiety, nervousness, and mood symptom relief
Both Gudise 2024 and Ademola 2025 documented improvements in anxiety and mood-related symptoms. Ademola 2025 showed significant changes in esteem-related affect (p=0.025) and mood improvement (p=0.008) — supporting Shatavari's traditional role as both rasayana (rejuvenative) and adaptogen.
Vaginal dryness and libido improvement
Gudise 2024 reported significant reduction in vaginal dryness and improvement in libido vs placebo — symptoms often inadequately addressed by other phytoestrogen approaches. Mechanism likely combines mild phytoestrogenic activity with adaptogenic stress modulation.
Quality of life improvement
Utian QoL score improved significantly in the Shatavari group vs placebo in Gudise 2024. The MENQOL (Menopause-Specific Quality of Life Questionnaire) and POMS scores in Ademola 2025 also showed numerical improvements.
Mechanism of action
Phytoestrogenic activity of Shatavarins
Shatavarin saponins have a steroidal structure resembling endogenous estrogens and bind weakly to estrogen receptors. This selective estrogen receptor modulator (SERM)-like activity provides menopausal symptom relief via the estrogen pathway without the higher-affinity binding that creates cancer concerns with conventional HRT.
Adaptogenic HPA-axis modulation
Shatavari is classified as a rasayana in Ayurveda — a category overlapping with the modern adaptogen concept. Animal models show modulation of the hypothalamic-pituitary-adrenal axis and reduced cortisol response to stressors. This contributes to anxiety reduction and improved sleep beyond the phytoestrogen mechanism.
GABAergic and 5-HT receptor effects
Preclinical work has identified GABAergic activity and serotonergic receptor modulation by Shatavari extracts — mechanisms that could contribute to anxiolytic and sleep-promoting effects. These pathways complement the phytoestrogen action and may explain why effects on mood symptoms are stronger than would be predicted from estrogen-receptor binding alone.
Antioxidant and anti-inflammatory activity
Asparagus racemosus root contains saponins, isoflavones, and polysaccharides with documented antioxidant activity. These reduce oxidative stress associated with the post-menopausal state, supporting a broader healthy-aging mechanism beyond direct symptom relief.
Clinical trials
Double-blind, multicenter, randomized, placebo-controlled clinical trial (Gudise VS, Dasari MP, Kuricheti SSK 2024, Cureus 16(4):e57879, doi:10.7759/cureus.57879). The test product was Aspurūs™ — full-spectrum Asparagus racemosus root extract standardized to 5% total Shatavarins (steroidal saponins) by HPTLC.
70 peri- and postmenopausal women aged 40-65 years experiencing menopausal symptoms (hot flashes, night sweats, anxiety, fatigue, depression, insomnia, mood swings). Randomized to two groups: Aspurūs™ test group (n=35) or microcrystalline cellulose placebo (n=35).
Aspurūs™ produced positive and significant effects vs placebo in: hot flashes, night sweats, insomnia, anxiety, nervousness, vaginal dryness, and loss of libido. Utian QoL score improved significantly in the active group vs placebo. No significant adverse events recorded. Authors concluded the formulation is a safe alternative to HRT, supporting traditional Ayurvedic use of Shatavari for menopausal symptoms.
8-week, randomized, double-blind, placebo-controlled, multicentric study (Ademola, Ajgaonkar, Debnath, Debnath, Langade 2025, Frontiers in Reproductive Health, doi:10.3389/frph.2025.1654503).
135 women aged 45-65 years with menopausal symptoms. Three groups: Shatavari root extract 300 mg (n=45), Ashwagandha + Shatavari combination (n=45), or placebo (n=45).
MRS (Menopause Rating Scale) scores improved at weeks 4 and 8. Esteem-related affect improved (p=0.025) and mood improved significantly (p=0.008) between groups. MENQOL scores improved numerically by week 8. Normal hormonal levels were maintained — no estrogenic stimulation in pituitary-ovarian axis. Mild adverse events reported in 4 participants (loose stools, dizziness, nausea, headache). Authors concluded the Ashwagandha + Shatavari combination demonstrated a promising option for managing menopausal symptoms.